GlassScriptPhysician profile
Khagendra Dahal
NPI 1851521892
$42,139.38
in general payments reported to CMS, 2019-2025
23 companies · $3,796 in 2025
The $3,796 reported for 2025 was more than what 79% of Interventional Cardiology providers received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,674 · 2020: $82.97 · 2021: $242 · 2022: $1,590 · 2023: $816 · 2024: $33K · 2025: $3,796.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Grant: $30K · Food and Beverage: $4,668 · Travel and Lodging: $2,633 · Education: $248.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Grant | $30,000.00 |
| Food and Beverage | $4,667.63 |
| Travel and Lodging | $2,633.41 |
| Education | $248.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $32,170.96 | 2024-2025 | Corevalve Evolut R, Symplicity G3, Onyx Frontier |
| Boston Scientific Corporation | $2,457.50 | 2019-2022 | |
| Abbott Laboratories | $2,184.52 | 2020-2025 | Prostar, Mitraclip, Navitor |
| Edwards Lifesciences Corporation | $2,158.32 | 2024-2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv), Sapien 3 Ultra Resilia |
| W. L. Gore & Associates, INC. | $1,605.98 | 2025 | Gore Cardioform Asd Occluder, Gore Cardioform Septal Occluder, Gore Excluder Thoracoabdominal Branch Endoprosthesis |
| Novartis Pharmaceuticals Corporation | $232.81 | 2021-2024 | |
| Amgen INC. | $221.72 | 2019-2023 | Repatha |
| Inari Medical, INC. | $197.02 | 2023 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Cook Medical LLC | $130.11 | 2019-2025 | Zilver Ptx |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $123.03 | 2019-2025 | Lifevest |
| Shockwave Medical, INC | $104.77 | 2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $93.64 | 2021-2024 | Jardiance |
| Cardinal Health 200 LLC | $91.80 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $81.89 | 2021-2023 | |
| Novo Nordisk INC | $50.00 | 2025 | Wegovy |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $49.21 | 2023 | |
| Chiesi USA, INC. | $43.38 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $28.95 | 2020-2023 | Farxiga |
| Scpharmaceuticals INC. | $28.19 | 2023-2024 | |
| Merck Sharp & Dohme LLC | $27.38 | 2023 | Verquvo |
| Janssen Pharmaceuticals, INC | $26.69 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $25.83 | 2019 | |
| Cardiovascular Systems INC. | $5.68 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Khagendra Dahal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.